Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH 2017 | Adapting AML treatment for elderly patients

Lars Bullinger • 12 Oct 2017
ESH 2017
Acute Myeloid Leukemia Azacitidine Decitabine Venetoclax

The effective use of the correct medication can greatly improve the chance of remission for patients with acute myeloid leukemia (AML). In this insightful video, Lars Bullinger, MD, from Charité University of Medicine, Berlin, Germany, speaking from the International Conference of Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Hematology (ESH), highlights the optimal combination therapies to combat AML in elderly patients and speculates about the future of this area.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Lars Bullinger

Bringing precision medicine and MRD into clinical strategies
1:49
Bringing precision medicine and MRD into clinical strategies
Lars Bullinger • 15 Jun 2020
Minimal gene panel in AML
1:56
Minimal gene panel in AML
Lars Bullinger • 15 Jun 2020
EHA: AML immuno-oncology updates
2:09
EHA: AML immuno-oncology updates
Lars Bullinger • 15 Jun 2020
Innovations in MDS and AML treatment
1:36
Innovations in MDS and AML treatment
Lars Bullinger • 15 Jun 2020

Related Videos

Dapolsertib in AML: results from the Phase I/II DIAMOND-01 trial
8:41
Dapolsertib in AML: results from the Phase I/II DIAMOND-01 trial
Roland Walter • 20 Sep 2026
Combination strategies in AML: triplets, targeted therapies and venetoclax resistance
8:33
Combination strategies in AML: triplets, targeted therapies and venetoclax resistance
Hima Atluri • 20 Sep 2026
How and when to use oral decitabine in AML
12:38
How and when to use oral decitabine in AML
Gail Roboz • 20 Sep 2026
A new era for AML? Lower-intensity frontline therapy and results from the Phase II PARADIGM trial
22:07
A new era for AML? Lower-intensity frontline therapy and results from the Phase II PARADIGM trial
Amir Fathi • 20 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals